Melioidosis

Melioidosis
Burkholderia pseudomallei
Specialty Infectious disease Edit this on Wikidata

Melioidosis is an infectious disease caused by a Gram-negative bacterium, Burkholderia pseudomallei, found in soil and water. It is of public health importance in endemic areas, particularly in northeast Thailand, Vietnam, and northern Australia. It exists in acute and chronic forms. Signs and symptoms may include pain in chest, bones, or joints; cough; skin infections, lung nodules, and pneumonia.

B. pseudomallei was previously classed as part of the genus Pseudomonas; until 1992, it was known as Pseudomonas pseudomallei. It is phylogenetically related closely to Burkholderia mallei which causes glanders, an infection primarily of horses, donkeys, and mules. The name melioidosis is derived from the Greek melis (μηλις) meaning "a distemper of asses" with the suffixes -oid meaning "similar to" and -osis meaning "a condition", that is, a condition similar to glanders.[1]

Signs and symptoms

Acute melioidosis

In the subgroup of patients where an inoculating event was noted, the mean incubation period of acute melioidosis was 9 days (range 1–21 days).[2] Patients with latent melioidosis may be symptom-free for decades; the longest period between presumed exposure and clinical presentation is 62 years.[3] The potential for prolonged incubation was recognized in US servicemen involved in the Vietnam War, and was referred to as the "Vietnam time-bomb". A wide spectrum of severity exists; in chronic presentations, symptoms may last months, but fulminant infection, particularly associated with near-drowning, may present with severe symptoms over hours.

Symptoms usually appear 2 to 4 weeks after exposure. There are four general types of infection including localized, pulmonary, blood-borne, or disseminated throughout the body. The type and location of the infection usually determines which symptoms appear first as well as which symptoms are more prominent.[4]

Patients with melioidosis usually present with fever. Pain or other symptoms may be suggestive of a clinical focus, which is found in around 75% of patients. Such symptoms include cough or pleuritic chest pain suggestive of pneumonia, bone or joint pain suggestive of osteomyelitis or septic arthritis, or cellulitis. Intra-abdominal infection (including liver and/or splenic abscesses, or prostatic abscesses) do not usually present with focal pain, and imaging of these organs using ultrasound or computed tomography should be performed routinely. In one series of 214 patients, 27.6% had abscesses in the liver or spleen (95% confidence interval, 22.0% to 33.9%). B. pseudomallei abscesses may have a characteristic "honeycomb" or "swiss cheese" architecture (hypoechoic, multiseptate, multiloculate) on CT.[5][6]

Regional variations in disease presentation are seen: parotid abscesses characteristically occur in Thai children, but this presentation has been described only once in Australia.[7] Conversely, prostatic abscesses are found in up to 20% of Australian males, but are rarely described elsewhere. An encephalomyelitis syndrome is recognised in northern Australia.

Patients with melioidosis usually have risk factors for disease, such as diabetes, thalassemia, hazardous alcohol use, or renal disease, and frequently give a history of occupational or recreational exposure to mud or pooled surface water.[8] However, otherwise healthy patients, including children, may also get melioidosis.

In up to 25% of patients, no focus of infection is found and the diagnosis is usually made on blood cultures or throat swab. Melioidosis is said to be able to affect any organ in the body except the heart valves (endocarditis). Although meningitis has been described secondary to ruptured brain abscesses, primary meningitis has not been described. Less common manifestations include intravascular infection, lymph node abscesses (1.2–2.2%),[9] pyopericardium and myocarditis, mediastinal infection, and thyroid and scrotal abscesses and ocular infection.

Chronic melioidosis

Chronic melioidosis is usually defined by a duration of symptoms greater than two months and occurs in about 10% of patients.[10] The clinical presentation of chronic melioidosis is protean and includes such presentations as chronic skin infections, chronic lung nodule, and pneumonia. In particular, chronic melioidosis closely mimics tuberculosis, and has sometimes been called "Vietnamese tuberculosis".[11][12][13]

Diagnosis

A definitive diagnosis is made by culturing the organism from any clinical sample, because the organism is never part of the normal human flora.

A definite history of contact with soil may not be elicited, as melioidosis can be dormant for many years before manifesting.[14] Attention should be paid to a history of travel to endemic areas in returned travellers. Some authors recommend considering possibility of melioidosis in every febrile patient with a history of traveling to and/or staying at endemic areas.

A complete screen (blood culture, sputum culture, urine culture, throat swab, and culture of any aspirated pus) should be performed on all patients with suspected melioidosis (culture on blood agar as well as Ashdown's medium). A definitive diagnosis is made by growing B. pseudomallei from any site. A throat swab is not sensitive, but is 100% specific if positive, and compares favourably with sputum culture.[15] The sensitivity of urine culture is increased if a centrifuged specimen is cultured, and any bacterial growth should be reported (not just growth above 104 organisms/ml which is the usual cutoff).[16] Very occasionally, bone marrow culture may be positive in patients who have negative blood cultures for B. pseudomallei, but these are not usually recommended.[17] A common error made by clinicians unfamiliar with melioidosis is to send a specimen from only the affected site (which is the usual procedure for most other infections) instead of sending a full screen.

Ashdown's medium, a selective medium containing gentamicin, may be required for cultures taken from nonsterile sites. Burkholderia cepacia medium may be a useful alternative selective medium in nonendemic areas, where Ashdown's is not available.[18] A new medium derived from Ashdown, known as Francis medium, may help differentiate B. pseudomallei from B. cepacia and may help in the early diagnosis of melioidosis,[19] but has not yet been extensively clinically validated.

Many commercial kits for identifying bacteria may misidentify B. pseudomallei (see Burkholderia pseudomallei for a more detailed discussion of this topic).

A serological test for melioidosis (indirect haemagglutination) is available, but not commercially in most countries. A high background titre may reduce the positive predictive value of serological tests in endemic countries. A specific direct immunofluorescent test and latex agglutination, based on monoclonal antibodies, are used widely in Thailand, but are not available elsewhere. Cross-reactivity with B. thailandensis is almost complete.[20] A commercial ELISA kit for melioidosis appears to perform well.[21] but no ELISA test has yet been clinically validated as a diagnostic tool.[22]

It is not possible to make the diagnosis on imaging studies alone (X-rays and scans),[23] but imaging is routinely performed to assess the full extent of disease.[24] Imaging of the abdomen using CT scans or ultrasound is recommended routinely, as abscesses may not be clinically apparent and may coexist with disease elsewhere. Australian authorities suggest imaging of the prostate specifically due to the high incidence of prostatic abscesses in northern Australian patients. A chest X-ray is also considered routine, with other investigations as clinically indicated. The presence of honeycomb abscesses in the liver is considered characteristic, but is not diagnostic.[23][24]

The differential diagnosis is extensive; melioidosis may mimic many other infections, including tuberculosis.[11]

Prevention

Person-to-person transmission is exceedingly unusual;[25][26][27] and patients with melioidosis should not be considered contagious. Lab workers should handle B. pseudomallei under BSL-3 isolation conditions,[28] as laboratory-acquired melioidosis has been described.

In endemic areas, people (rice-paddy farmers in particular) are warned to avoid contact with soil, mud, and surface water where possible. Case clusters have been described following flooding and cyclones and probably relate to exposure. Other case clusters have related to contamination of drinking water supplies. Populations at risk include patients with diabetes mellitus, chronic renal failure, chronic lung disease, or an immune deficiency of any kind. The effectiveness of measures to reduce exposure to the causative organism have not been established. A vaccine is not yet available.

Postexposure prophylaxis

After exposure to B. pseudomallei (particularly following a laboratory accident) combined treatment with co-trimoxazole and doxycycline is recommended.[29][30] Trovafloxacin and grepafloxacin have been shown to be effective in animal models.[31]

Vaccination

A vaccine is in the process of being developed, but is not yet licensed. There is a fear that when a vaccine is licensed, financial constraints will make the vaccination an unrealistic factor for many countries that are suffering from high rates of melioidosis.[32]

Treatment

Current treatment

The treatment of melioidosis is divided into two stages, an intravenous high-intensity phase and an eradication phase to prevent recurrence.

Intravenous intensive phase
Intravenous ceftazidime is the current drug of choice for treatment of acute melioidosis and should be administered 10 to 14 days after getting the infection.[4][33][34] Meropenem,[35] imipenem[2] and the cefoperazone-sulbactam combination (Sulperazone)[36] are also active.[37] Intravenous amoxicillin-clavulanate (co-amoxiclav) may be used if none of the above four drugs is available, but it produces inferior outcomes.[38] Intravenous antibiotics are given for a minimum of 10 to 14 days, and are not usually stopped until the patient's temperature has returned to normal for more than 48 hours. Even with appropriate antibiotic therapy, fevers often persist for weeks or months, and patients may continue to develop new lesions even while on appropriate treatment. The median fever clearance time in melioidosis is 10 days:[38] and failure of the fever to clear is not a reason to alter treatment. It is not uncommon for patients to require parenteral treatment continuously for a month or more.
Intravenous meropenem is routinely used in Australia;[10] outcomes appear to be good and meropenem is currently being tested with ceftazidime in a Thai clinical trial.[39]
Theoretical reasons are given for believing mortality might be lower in patients treated with imipenem: first, less endotoxin is released by dying bacteria during imipenem treatment,[40] and the minimum inhibitory concentration (MIC) for imipenem is lower than for ceftazidime. However, no clinically relevant difference was found in mortality between imipenem and ceftazidime treatments.[2] The MIC of meropenem is higher for B. pseudomallei than for many other organisms, and patients being haemofiltered will need more frequent or higher doses.[41]
Moxifloxacin, cefepime, tigecycline, and ertapenem do not appear to be effective in vitro.[42][43] Piperacillin-sulbactam,[42] doripenem and biapenem[43][44] appear to be effective in vitro, but no clinical experience exists on which to recommend their use.
Adjunctive treatment with granulocyte colony-stimulating factor[45] or co-trimoxazole[46][47] were not associated with decreased fatality rates in trials in Thailand.
Eradication phase
Following the treatment of the acute disease, eradication (or maintenance) treatment with co-trimoxazole and doxycycline is recommended to be used for 12 to 20 weeks to reduce the rate of recurrence.[48] Chloramphenicol is no longer routinely recommended for this purpose. Co-amoxiclav is an alternative for those patients who are unable to take co-trimoxazole and doxycycline (e.g., pregnant women and children under the age of 12),[49][50] but is not as effective. Single agent treatment with a fluoroquinolone (e.g., ciprofloxacin)[51][52] or doxycycline[53] for the oral maintenance phase is ineffective.[54]
In Australia, co-trimoxazole is used on its own for eradication therapy,[10] with relapse rates that are lower than those seen in Thailand; in vitro evidence also suggests co-trimoxazole and doxycycline are antagonistic, and co-trimoxazole on its own may be preferable.[55] Results from a randomised controlled trial (MERTH) support the use of co-trimoxazole alone.[56] Studies reinforce the need for adequate follow-up and good adherence to the eradication phase of therapy. Dosing for co-trimoxazole is based on weight: (<40 kg: 160/800 mg every 12 hours; 40–60kg: 240/1200 mg every 12 hours, >60 kg: 320/1600 mg every 12 hours).[57]

Surgical treatment

Surgical drainage is usually indicated for prostatic abscesses and septic arthritis, may be indicated for parotid abscesses, and is not usually indicated for hepatosplenic abscesses. In bacteraemic melioidosis unresponsive to intravenous antibiotic therapy, splenectomy has been attempted, but only anecdotal evidence supports this practice.[58]

Historical treatment

Prior to 1989, the standard treatment for acute melioidosis was a three-drug combination of chloramphenicol, co-trimoxazole and doxycycline; this regimen is associated with a mortality rate of 80% and is no longer be used unless no other alternatives are available.[33] All three drugs are bacteriostatic (they stop the bacterium from growing, but do not kill it) and the action of co-trimoxazole antagonizes both chloramphenicol and doxycycline.[59]

Prognosis

Without access to appropriate antibiotics (principally ceftazidime or meropenem), the septicemic form of melioidosis exceeds 90% in mortality rate.[60][61] With appropriate antibiotics, the mortality rate is about 10% for uncomplicated cases but up to 80% for cases with bacteraemia or severe sepsis. It seems certain that access to intensive care facilities is also important, and probably at least partially explains why total mortality is 20% in Northern Australia but 40% in Northeast Thailand. Response to appropriate antibiotic treatment is slow, with the average duration of fever following treatment being 5 to 9 days.[62][63]

Recurrence occurs in 10 to 20% of patients, but with co-trimoxazole eradication therapy, this can be reduced to 4%.[64] While molecular studies have established the majority of recurrences are due to the original infecting strain, a significant proportion of recurrences (perhaps up to a quarter) in endemic areas may be due to reinfection, particularly after two years.[65] Risk factors include severity of disease (patients with positive blood cultures or multifocal disease have a higher risk of relapse), choice of antibiotic for eradication therapy (doxycycline monotherapy and fluoroquinolone therapy are not as effective), poor compliance with eradication therapy and duration of eradication therapy less than 8 weeks.[54][66]

Biological warfare potential

Interest in melioidosis has been expressed because it has the potential to be developed as a biological weapon. It is classed by the US Centers for Disease Control (CDC) as a category B agent.[67] B. pseudomallei, like B. mallei which causes glanders, was studied by the US as a potential biological warfare agent, but never weaponized.[68] The Soviet Union was reported to have also experimented with B. pseudomallei as a biological warfare agent.

Epidemiology

Global map showing the distribution of melioidosis from 1910 to 2014

Melioidosis is endemic in parts of southeast Asia (including Thailand,[69] Laos,[70][71][72] Singapore,[73] Brunei,[74] Malaysia, Burma and Vietnam), China,[75] Taiwan[76][77] and northern Australia.[62][78] Flooding can increase its extent, including flooding in central Australia.[79] Multiple cases have also been described in Hong Kong and Brunei[80] India,[81][82][83][84] and sporadic cases in Central and South America,[85][86][87] the Middle East, the Pacific and several African countries.[88][89] Although only one case of melioidosis has ever been reported in Bangladesh,[90] at least five cases have been imported to the UK from that country. Recent news reports indicate B. pseudomallei has been isolated from soil in Bangladesh,[91] but this remains to be verified scientifically. This suggests that melioidosis is endemic to Bangladesh and that a problem of underdiagnosis or under-reporting exists there.[92] most likely due to a lack of adequate laboratory facilities in affected rural areas. A high isolation frequency (percentage of positive soil samples) was found in east Saravan in rural Lao PDR distant from the Mekong River, thought by the investigators to be the highest geometric mean concentration in the world (about 464 (25-10,850 CFU/g soil).[93]

A statistical model indicated that the incidence will be 165,000 cases per year in 2016 (95% confidence interval, 68,000 to 412,000), with 138,000 of those occurring in East and South Asia and the Pacific.[94] In about half of those cases, people will die. Northeast Thailand has the highest incidence of melioidosis recorded in the world (an average incidence of 12.7 cases per 100,000 people per year).[95] In Northeast Thailand, 80% of children are positive for antibodies against B. pseudomallei by the age of 4;[96] the figures are lower in other parts of the world.[97][98][99][100]

Melioidosis is a recognised disease in animals, including cats,[101] goats, sheep, and horses. Cattle, water buffalo, and crocodiles are considered to be relatively resistant to melioidosis despite their constant exposure to mud.[102] An outbreak at the Paris Zoo in the 1970s ("L’affaire du jardin des plantes") was thought to have originated from an imported panda.[103]

B. pseudomallei is normally found in soil and surface water; a history of contact with soil or surface water is, therefore, almost invariable in patients with melioidosis;[62] that said, the majority of patients who do have contact with infected soil suffer no ill effects. Even within an area, the distribution of B. pseudomallei within the soil can be extremely patchy,[104][105] and competition with other Burkholderia species has been suggested as a possible reason.[106] Contaminated ground water was implicated in one outbreak in northern Australia.[107] Also implicated are severe weather events such as flooding[108] tsunamis[109] and typhoons.[110][111]

Based on whole genome sequencing, humans may play a role in moving B. pseudomallei from place to place.[112]

The single most important risk factor for developing melioidosis is diabetes mellitus, followed by hazardous alcohol use, chronic kidney disease, and chronic lung disease. Other risk factors include thalassaemia, occupation (rice paddy farmers),[113] and cystic fibrosis.[25][86] The mode of infection is believed to be through either a break in the skin, or the inhalation of aerosolized B. pseudomallei cells. Person-to-person spread has been described, but is extremely unusual.[25][26][27] HIV infection does not predispose to melioidosis.[114][115][116]

The disease is clearly associated with increased rainfall, with the number (and severity) of cases rising following increased precipitation.[73][117][118][119][120][121]

History

Pathologist Alfred Whitmore and assistant Krishnaswami first reported the disease among beggars and morphine addicts at autopsy in Rangoon, present-day Myanmar, in a report published in 1912.[122] They distinguished it from glanders, a disease of humans and animals that is similar in presentation, but caused by a different micro-organism. B. pseudomallei, also known as the Whitmore bacillus, was identified in 1917 in Kuala Lumpur.[123] Arthur Conan Doyle may have read the 1912 report before writing a short story that involved the fictitious tropical disease "tapanuli fever" in a Sherlock Holmes adventure.[124]

Synonyms

References

  1. ↑ Stanton AT, Fletcher W (1921). "Melioidosis, a new disease of the tropics". Far Eastern Association of Tropical Medicine: Transactions of the Fourth Congress. Batavia, Dutch East Indies: Javasche Boekhandel en Drukkerij.
  2. 1 2 3 A J Simpson; Suputtamongkol Y; Smith MD; et al. (1999). "Comparison of imipenem and ceftazidime as therapy for severe melioidosis". Clinical Infectious Diseases. 29 (2): 381&ndash, 387. doi:10.1086/520219. PMID 10476746.
  3. ↑ Ngauy V, Lemeshev Y, Sadkowski L, Crawford G (2005). "Cutaneous Melioidosis in a Man Who Was Taken as a Prisoner of War by the Japanese during World War II". Journal of Clinical Microbiology Microb. 43 (2): 970&ndash, 972. doi:10.1128/JCM.43.2.970-972.2005. PMC 548040. PMID 15695721.
  4. 1 2 Centers for Disease Control and Prevention. Melioidosis. 2012. Accessed February 27, 2017.
  5. ↑ Apisarnthanarak A, Apisarnthanarak P, Mundy LM (2006). "Computer tomography characteristics of Burkholderia pseudomallei liver abscess". Clinical Infectious Diseases. 42 (7): 989&ndash, 993. doi:10.1086/501017. PMID 16511765.
  6. ↑ Laopaiboon V, Chamadol N, Buttham H, Sukeepaisarnjareon W (2009). "CT findings of liver and splenic abscesses in melioidosis: comparison with those in non-melioidosis". Journal of the Medical Association of Thailand. 92 (11): 1476&ndash, 1484. PMID 19938740.
  7. ↑ Dance DA, Davis TM, Wattanagoon Y, et al. (1989). "Acute suppurative parotitis caused by Pseudomonas pseudomallei in children". Journal of Infectious Diseases. 159 (4): 654&ndash, 660. doi:10.1093/infdis/159.4.654. PMID 2926159.
  8. ↑ Raja, NS; Ahmed MZ; Singh NN (1 April 2005). "Melioidosis: an emerging infectious disease". Journal of Postgraduate Medicine. 51 (2): 140&ndash, 145. PMID 16006713.
  9. ↑ Chlebicki, MP; Tan BH (2006). "Six cases of suppurative lymphadenitis caused by Burkholderia pseudomallei infection". Transactions of the Royal Society of Tropical Medicine and Hygiene. 100 (8): 798&ndash, 801. doi:10.1016/j.trstmh.2005.10.004. PMID 16542691.
  10. 1 2 3 Currie BJ, Fisher DA, Howard DM, et al. (2000). "Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature". Clinical Infectious Diseases. 31 (4): 981&ndash, 986. doi:10.1086/318116. PMID 11049780.
  11. 1 2 Falade OO, Antonarakis ES, Kaul DR, Saint S, Murphy PA (2008). "Clinical problem-solving. Beware of first impressions". New England Journal of Medicine. 359 (6): 628&ndash, 634. doi:10.1056/NEJMcps0708803. PMC 4007002. PMID 18687644.
  12. ↑ Chetchotisakd, P; Anunnatsiri, S; Kiatchoosakun, S; Kularbkaew, C (2010). "Melioidosis pericarditis mimicking tuberculous pericarditis". Clinical Infectious Diseases. 51 (5): e46–49. doi:10.1086/655699. PMID 20645861.
  13. ↑ Suntornsut P, Kasemsupat K, Silairatana S, et al. (2013). "Prevalence of Melioidosis in Patients with Suspected Pulmonary Tuberculosis and Sputum Smear Negative for Acid-Fast Bacilli in Northeast Thailand". American Journal of Tropical Medicine and Hygiene. 89 (5): 983&ndash, 985. doi:10.4269/ajtmh.13-0286. PMC 3820347. PMID 24062474.
  14. ↑ Ngauy V, Lemeshev Y, Sadkowski L, Crawford G (2005). "Cutaneous Melioidosis in a Man Who Was Taken as a Prisoner of War by the Japanese during World War II". Journal of Clinical Microbiology. 43 (2): 970&ndash, 972. doi:10.1128/JCM.43.2.970-972.2005. PMC 548040. PMID 15695721.
  15. ↑ Wuthiekanun V, Suputtamongkol Y, Simpson AJ, Kanaphun P, White NJ (2001). "Value of Throat Swab in Diagnosis of Melioidosis". Journal of Clinical Microbiology. 39 (10): 3801&ndash, 3802. doi:10.1128/JCM.39.10.3801-3802.2001. PMC 88440. PMID 11574624.
  16. ↑ Limmathurotsakul D, Wuthiekanun V, Chierakul W, et al. (2005). "Role and Significance of Quantitative Urine Cultures in Diagnosis of Melioidosis". Journal of Clinical Microbiology. 43 (5): 2274&ndash, 2276. doi:10.1128/JCM.43.5.2274-2276.2005. PMC 1153798. PMID 15872255.
  17. ↑ Dance DA, White NJ, Suputtamongkol Y, Wattanagoon Y, Wuthiekanun V, Chaowagul W (1990). "The use of bone marrow culture for the diagnosis of melioidosis". Transactions of the Royal Society of Tropical Medicine and Hygiene. 84 (4): 585&ndash, 587. doi:10.1016/0035-9203(90)90050-O. PMID 2091358.
  18. ↑ Peacock SJ, Chieng G, Cheng AC, et al. (2005). "Comparison of Ashdown's Medium, Burkholderia cepacia Medium, and Burkholderia pseudomallei Selective Agar for Clinical Isolation of Burkholderia pseudomallei". Journal of Clinical Microbiology. 43 (10): 5359&ndash, 5361. doi:10.1128/JCM.43.10.5359-5361.2005. PMC 1248505. PMID 16208018.
  19. ↑ Francis A, Aiyar S, Yean C, Naing L, Ravichandran M (2006). "An improved selective and differential medium for the isolation of Burkholderia pseudomallei from clinical specimens". Diagnostic Microbiology and Infectious Diseases. 55 (2): 95&ndash, 99. doi:10.1016/j.diagmicrobio.2005.11.008. PMID 16626918.
  20. ↑ Puthucheary SD, Anuar AS, Tee TS (2010). "Burkholderia thailandensis whole cell antigen cross-reacts with B. pseudomallei antibodies from patients with melioidosis in an immunofluorescent assay". The Southeast Asian Journal of Tropical Medicine and Public Health. 41 (2): 397&ndash, 400. PMID 20578523.
  21. ↑ Limmathurotsakul D, Chantratita N, Teerawattanasook N, et al. (2011). "Enzyme-Linked Immunosorbent Assay for the Diagnosis of Melioidosis: Better Than We Thought". Clinical Infectious Diseases. 52 (8): 1024&ndash, 1028. doi:10.1093/cid/cir080. PMC 3070030. PMID 21460318.
  22. ↑ Peacock SJ, Cheng AC, Currie BJ, Dance DA (2011). "The Use of Positive Serological Tests as Evidence of Exposure to Burkholderia pseudomallei". American Journal of Tropical Medicine and Hygiene. 84 (6): 1021&ndash, 1022. doi:10.4269/ajtmh.2011.11-0114a. PMC 3110358. PMID 21633045.
  23. 1 2 Lim KS, Chong VH (2010). "Radiological manifestations of melioidosis". Clinical Radiology. 65 (1): 66&ndash, 72. doi:10.1016/j.crad.2009.08.008. PMID 20103424.
  24. 1 2 Muttarak M, Peh WC, Euathrongchit J, Lin SE, Tan AG, Lerttumnongtum P, Sivasomboon C (2008). "Spectrum of imaging findings in melioidosis". British Journal of Radiology. 82 (978): 514–521. doi:10.1259/bjr/15785231. PMID 19098086.
  25. 1 2 3 Holland DJ, Wesley A, Drinkovic D, Currie BJ (2002). "Cystic fibrosis and Burkholderia pseudomallei infection: an emerging problem?". Clinical Infectious Diseases. 35 (12): e138&ndash, 140. doi:10.1086/344447. PMID 12471591.
  26. 1 2 McCormick J B (1975). "Human-to-human transmission of Pseudomonas pseudomallei". Annals of Internal Medicine. 83 (4): 512&ndash, 513. doi:10.7326/0003-4819-83-4-512.
  27. 1 2 Kunakorn M, Jayanetra P, Tanphaichitra D (1991). "Man-to-man transmission of melioidosis". Lancet. 337 (8752): 1290&ndash, 1291. doi:10.1016/0140-6736(91)92962-2. PMID 1674089.
  28. ↑ Centers for Disease Control and Prevention (2009). Biosafety in Microbiological and Biomedical Laboratories (5th ed.). Atlanta, Georgia: National Institutes of Health.
  29. ↑ Sivalingam SP, Sim SH, Jasper LC, et al. (2008). "Pre- and post-exposure prophylaxis of experimental Burkholderia pseudomallei infection with doxycycline, amoxicillin/clavulanic acid and co-trimoxazole". Journal of Antimicrobial Chemotherapy. 61 (3): 674&ndash, 678. doi:10.1093/jac/dkm527. PMID 18192684.
  30. ↑ Peacock SJ, Schweizer HP, Dance DA, et al. (2008). "Management of Accidental Laboratory Exposure to Burkholderia pseudomallei and B. mallei". Emerging Infectious Diseases. 14 (7): e2. doi:10.3201/eid1407.071501. PMC 2600349. PMID 18598617.
  31. ↑ Kenny DJ, Sefton AM, Brooks TJ, Laws TR, Simpson AJ, Atkins HS (2010). "Evaluation of azithromycin, trovafloxacin and grepafloxacin as prophylaxis for experimental murine melioidosis". International Journal of Antimicrobial Agents. 36 (1): 87–89. doi:10.1016/j.ijantimicag.2010.03.019. PMID 20462743.
  32. ↑ Cheng AC, Currie BJ (2005). "Melioidosis: Epidemiology, Pathophysiology, and Management". Clinical Microbiology Reviews. 18 (2): 383–416. doi:10.1128/CMR.18.2.383-416.2005.
  33. 1 2 White NJ, Dance DA, Chaowagul W, et al. (1989). "Halving of mortality of severe melioidosis by ceftazidime". Lancet. 2 (8665): 697&ndash, 701. doi:10.1016/S0140-6736(89)90768-X. PMID 2570956.
  34. ↑ Chierakul W, Anunnatsiri S, Chaowagul W, et al. (2007). "Addition of trimethoprim-sulfamethoxazole to ceftazidime during parenteral treatment of melioidosis is not associated with a long-term outcome benefit". Clinical Infectious Diseases. 45 (4): 521&ndash, 523. doi:10.1086/520010. PMID 17638209.
  35. ↑ Cheng AC, Fisher DA, Anstey NM, et al. (2004). "Outcomes of Patients with Melioidosis Treated with Meropenem". Antimicrob Agents Chemother. 48 (5): 1763&ndash, 65. doi:10.1128/AAC.48.5.1763-1765.2004. PMC 400582. PMID 15105132.
  36. ↑ Chetchotisakd P, Porramatikul S, Mootsikapun P, Anunnatsiri S, Thinkhamrop B (2001). "Randomized, double-blind, controlled study of cefoperazone-sulbactam plus cotrimoxazole versus ceftazidime plus cotrimoxazole for the treatment of severe melioidosis". Clinical Infectious Diseases. 33 (1): 29&ndash, 33. doi:10.1086/320878. PMID 11389491.
  37. ↑ Dance DA, Wuthiekanun V, White NJ, Chaowagul W (1988). "Antibiotic resistance in Pseudomonas pseudomallei". Lancet. 1 (8592): 994&ndash, 995. doi:10.1016/S0140-6736(88)91810-7. PMID 2896855.
  38. 1 2 Suputtamongkol Y, Rajchanuwong A, Chaowagul W, et al. (1994). "Ceftazidime vs. amoxicillin/clavulanate in the treatment of severe melioidosis". Clinical Infectious Diseases. 19 (5): 846&ndash, 853. doi:10.1093/clinids/19.5.846. PMID 7893868.
  39. ↑ University of Oxford (18 December 2007). "A randomized double blinded comparison of ceftazidime and meropenem in severe melioidosis (ATOM)". ClinicalTrials.gov. National Institutes of Health. Retrieved 27 Jan 2011.
  40. ↑ Simpson, A. J. H.; Opal, S. M.; Angus, B. J.; Prins, J. M.; Palardy, J. E.; Parejo, N. A.; Chaowagul, W.; White, N. J. (2000). "Differential antibiotic-induced endotoxin release in severe melioidosis". Journal of Infectious Diseases. 181 (3): 1014&ndash, 1019. doi:10.1086/315306. PMID 10720525.
  41. ↑ Bilgrami, I.; Roberts, J. A.; Wallis, S. C.; Thomas, J.; Davis, J.; Fowler, S.; Goldrick, P. B.; Lipman, J. (2010). "Meropenem Dosing in Critically Ill Patients with Sepsis Receiving High-Volume Continuous Venovenous Hemofiltration". Antimicrobial Agents and Chemotherapy. 54 (7): 2974–2978. doi:10.1128/AAC.01582-09. PMC 2897321. PMID 20479205.
  42. 1 2 Shih H-I; Chuang Y-C; Cheung BM-H; et al. (February 2008). "Sporadic and outbreak cases of melioidosis in southern Taiwan: clinical features and antimicrobial susceptibility". Infection. 37 (1): 9–15. doi:10.1007/s15010-008-7324-8. PMID 18854938.
  43. 1 2 Harris P, Engler C, Norton R (2011). "Comparative in vitro susceptibility of Burkholderia pseudomallei to doripenem, ertapenem, tigecycline and moxifloxacin". International Journal of Antimicrobia Agents. 37 (6): 547&ndash, 549. doi:10.1016/j.ijantimicag.2011.02.001.
  44. ↑ Thamlikitkul V, Trakulsomboon S (2010). "In vitro activity of biapenem against Burkholderia pseudomallei". International Journal of Antimicrobia Agents. 35 (5): 514. doi:10.1016/j.ijantimicag.2010.01.002. PMID 20188524.
  45. ↑ Cheng AC, Limmathurotsakul D, Chierakul W, et al. (2007). "A randomized controlled trial of granulocyte colony-stimulating factor for the treatment of severe sepsis due to melioidosis in Thailand". Clinical Infectious Diseases. 45 (3): 308&ndash, 314. doi:10.1086/519261. PMID 17599307.
  46. ↑ Chierakul W, Anunnatsiri S, Short JM, et al. (2005). "Two randomized controlled trials of ceftazidime alone versus ceftazidime in combination with trimethoprim-sulfamethoxazole for the treatment of severe melioidosis". Clinical Infectious Diseases. 41 (8): 1105&ndash, 1113. doi:10.1086/444456. PMID 16163628.
  47. ↑ Chierakul W, Anunnatsiri S, Chaowagul W, Peacock SJ, Chetchotisakd P, Day NP (2007). "Addition of trimethoprim-sulfamethoxazole to ceftazidime during parenteral treatment of melioidosis is not associated with a tong-term outcome benefit". Clinical Infectious Diseases. 45 (4): 521&ndash, 523. doi:10.1086/520010. PMID 17638209.
  48. ↑ Chaowagul W, Simpson AJ, Suputtamongkol Y, et al. (1999). "A comparison of chloramphenicol, trimethoprim-sulfamethoxazole, and doxycycline with doxycycline alone as maintenance therapy for melioidosis". Clinical Infectious Diseases. 29 (2): 375&ndash, 380. doi:10.1086/520218. PMID 10476745.
  49. ↑ Rajchanuvong A, Chaowagul W, Suputtamongkol Y, Smith MD, Dance DA, White NJ (1995). "A prospective comparison of co-amoxiclav and the combination of chloramphenicol, doxycycline, and co-trimoxazole for the oral maintenance treatment of melioidosis". Transactions of the Royal Society of Tropical Medicine and Hygiene. 89 (5): 546&ndash, 549. doi:10.1016/0035-9203(95)90104-3. PMID 8560537.
  50. ↑ Cheng AC, Chierakul W, Chaowagul W, et al. (2008). "Short Report: Consensus Guidelines for Dosing of Amoxicillin-Clavulanate in Melioidosis". American Journal of Tropical Medicine and Hygiene. 78 (2): 208&ndash, 209. PMC 3034162. PMID 18256414.
  51. ↑ Chaowagul W, Supputtamongkul Y, Smith MD, White NJ (1997). "Oral fluoroquinolones for maintenance treatment of melioidosis". Transactions of the Royal Society of Tropical Medicine and Hygiene. 91 (5): 599&ndash, 601. doi:10.1016/S0035-9203(97)90044-4. PMID 9463680.
  52. ↑ Chetchotisakd P, Chaowagul W, Mootsikapun P, Budhsarawong D, Thinkamrop B (Jan–Feb 2001). "Maintenance therapy of melioidosis with ciprofloxacin plus azithromycin compared with cotrimoxazole plus doxycycline". American Journal of Tropical Medicine and Hygiene. 64 (1&ndash, 2): 24&ndash, 27. doi:10.4269/ajtmh.2001.64.24. PMID 11425157.
  53. ↑ Chaowagul W,; Simpson, Andrew J. H.; Suputtamongkol, Yupin; Smith, Michael D.; Angus, Brian J.; White, Nicholas J. (August 1999). "Clin Infect Dis". Clinical Infectious Diseases. 29 (2): 375–380. doi:10.1086/520218. PMID 10476745.
  54. 1 2 Limmathurotsakul D; Chaowagul W; Chierakul Wirongrong; et al. (2006). "Risk factors for recurrent melioidosis in Northeastern Thailand". Clinical Infectious Diseases. 43 (8): 979&ndash, 986. doi:10.1086/507632. PMID 16983608.
  55. ↑ Dance DA, Wuthiekanun V, Chaowagul W, White NJ (1989). "Interactions in vitro between agents used to treat melioidosis". Journal of Antimicrobial Chemotherapy. 24 (3): 311&ndash, 316. doi:10.1093/jac/24.3.311. PMID 2681117.
  56. ↑ Chetchotisakd, P; Chierakul, W; Chaowagul, W; Anunnatsiri, S; Phimda, K; Mootsikapun, P; Chaisuksant, S; Pilaikul, J; Thinkhamrop, B; Phiphitaporn, S; Susaengrat, W; Toondee, C; Wongrattanacheewin, S; Wuthiekanun, V; Chantratita, N; Thaipadungpanit, J; Day, NP; Limmathurotsakul, D; Peacock, SJ (1 March 2014). "Trimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): a multicentre, double-blind, non-inferiority, randomised controlled trial". Lancet. 383 (9919): 807–814. doi:10.1016/S0140-6736(13)61951-0. PMC 3939931. PMID 24284287.
  57. ↑ Cheng AC, McBryde ES, Wuthiekanun V, Chierakul W, Amornchai P, Day NP, Peacock SJ (2009). "Dosing Regimens of Cotrimoxazole (Trimethoprim-Sulfamethoxazole) for Melioidosis". Antimicrobial Agents and Chemotherapy. 53 (10): 4193–4199. doi:10.1128/AAC.01301-08. PMC 2764189. PMID 19620336.
  58. ↑ TJ Inglis; CL Golledge; A Clair; J Harvey (2001). "Case report: recovery from persistent septicemic melioidosis". American Journal of Tropical Medicine and Hygiene. 65 (1): 76&ndash, 82. doi:10.4269/ajtmh.2001.65.76. PMID 11504412.
  59. ↑ Dance DA, Wuthiekanun V, Chaowagul W, White NJ (1989). "Interactions in vitro between agents used to treat melioidosis". Journal of Antimicrobial Chemotherapy. 24 (3): 311&ndash, 316. doi:10.1093/jac/24.3.311. PMID 2681117.
  60. ↑ Couture E (1935). "La Melioidosis Etat actuel de la question". Rev Hyg Méd Prèv. 57: 190.
  61. ↑ Warner JM, Pelowa DB, Currie BJ, Hirst RG (2007). "Melioidosis in a rural community of Western Province, Papua New Guinea". Transactions of the Royal Society of Tropical Medicine and Hygiene. 101 (8): 809–813. doi:10.1016/j.trstmh.2007.02.024. PMID 17499321.
  62. 1 2 3 White NJ (2003). "Melioidosis". Lancet. 361 (9370): 1715&ndash, 1722. doi:10.1016/S0140-6736(03)13374-0. PMID 12767750.
  63. ↑ Chaowagul W, White NJ, Dance DA, et al. (1989). "Melioidosis: a major cause of community-acquired septicemia in northeastern Thailand". Journal of Infectious Diseases. 159 (5): 890&ndash, 899. doi:10.1093/infdis/159.5.890. PMID 2708842.
  64. ↑ Sarovich DS, Ward L, Price EP, et al. (2014). "Recurrent melioidosis in the Darwin Prospective Melioidosis Study: improving therapies mean that relapse cases are now rare". Journal of Clinical Microbiology. 52 (2): 650&ndash, 653. doi:10.1128/JCM.02239-13. PMC 3911345. PMID 24478504.
  65. ↑ Maharjan B, Chantratita N, Vesaratchavest M, et al. (2005). "Recurrent Melioidosis in Patients in Northeast Thailand Is Frequently Due to Reinfection Rather than Relapse". Journal of Clinical Microbiology. 43 (12): 6032&ndash, 6034. doi:10.1128/JCM.43.12.6032-6034.2005. PMC 1317219. PMID 16333094.
  66. ↑ Chaowagul W, Suputtamongkol Y, Dance DA, Rajchanuvong A, Pattara-arechachai J, White NJ (1993). "Relapse in melioidosis: incidence and risk factors". Journal of Infectious Diseases. 168 (5): 1181&ndash, 1185. doi:10.1093/infdis/168.5.1181. PMID 8228352.
  67. ↑ CDC Disease Info melioidosis
  68. ↑ Withers MR (ed.) (2014). USAMRIID's Medical Management of Biological Casualties Handbook (PDF) (8th ed.). Fort Detrick, Maryland: U.S. Army Medical Institute of Infectious Diseases. p. 53.
  69. ↑ V Vuddhakul; et al. (1999). "Epidemiology of Burkholderia pseudomallei in Thailand". American Journal of Tropical Medicine and Hygiene. 60 (3): 458&ndash, 461. doi:10.4269/ajtmh.1999.60.458.
  70. ↑ Wuthiekanun V, Mayxay M, Chierakul W, Phetsouvanh R, Cheng AC, White NJ, Day NP, Peacock SJ (2005). "Detection of Burkholderia pseudomallei in soil within the Lao People's Democratic Republic". Journal of Clinical Microbiology. 43 (2): 923–924. doi:10.1128/JCM.43.2.923-924.2005. PMC 548109. PMID 15695707.
  71. ↑ Rattanavong S, Wuthiekanun V, Langla S, Amornchai P, Sirisouk J, Phetsouvanh R, Moore CE, Peacock SJ, Buisson Y, Newton PN (2010). "Randomized Soil Survey of the Distribution of Burkholderia pseudomallei in Rice Fields in Laos". Applied and Environmental Microbiology. 77 (2): 532–536. doi:10.1128/AEM.01822-10. PMC 3020526. PMID 21075883.
  72. ↑ Vongphayloth K, Rattanavong S, Moore CE, Phetsouvanh R, Wuthiekanun V, Sengdouangphachanh A, Phouminh P, Newton PN, Buisson Y (2012). "Burkholderia pseudomallei detection in surface water in southern Laos using Moore's swabs". American Journal of Tropical Medicine and Hygiene. 86 (5): 872&ndash, 877. doi:10.4269/ajtmh.2012.11-0739. PMC 3335696. PMID 22556090.
  73. 1 2 Lo TJ, Ang LW, James L, Goh KT (2009). "Melioidosis in a Tropical City State, Singapore". Emerging Infectious Diseases. 15 (10): 1645&ndash, 1647. doi:10.3201/eid1510.090246. PMC 2866399. PMID 19861063.
  74. ↑ Kadir KA, Satyavani M, Pande K (2014). "Melioidosis: Antibiogram of cases in Brunei Darussalam" (PDF). Brunei International Medical Journal. 10 (1): 19&ndash, 24.
  75. ↑ Yang S (2000). "Melioidosis research in China". Acta Tropica. 77 (2): 157&ndash, 165. doi:10.1016/S0001-706X(00)00139-X.
  76. ↑ Ko, WC; Cheung, BM; Tang, HJ; Shih, HI; Lau, YJ; Wang, LR; Chuang, YC (2007). "Melioidosis Outbreak after Typhoon, Southern Taiwan". Emerging Infectious Diseases. 13 (6): 896&ndash, 898. doi:10.3201/eid1306.060646. PMC 2792857. PMID 17553230.
  77. ↑ Chen YS, Lin HH, Mu JJ, Chiang CS, Chen CH, Buu LM, Lin YE, Chen YL (2010). "Distribution of Melioidosis Cases and Viable Burkholderia pseudomallei in Soil: Evidence for Emerging Melioidosis in Taiwan". Journal of Clinical Microbiology. 48 (4): 1432–1434. doi:10.1128/JCM.01720-09. PMC 2849618. PMID 20147639.
  78. ↑ Cheng AC, Currie BJ (2005). "Melioidosis: Epidemiology, Pathophysiology, and Management". Clinical Microbiology Reviews. 18 (2): 383&ndash, 416. doi:10.1128/CMR.18.2.383-416.2005. PMC 1082802. PMID 15831829.
  79. ↑ http://www.abc.net.au/news/2017-01-09/melioidosis-risk-spreads-to-central-australia-heavy-rain/8169824
  80. ↑ Chong VH (2010). "Changing spectrum of microbiology of liver abscess: Now Klebsiella, next Burkholderia pseudomallei". Journal of Emerging Medicine. 41 (6): 676–677. doi:10.1016/j.jemermed.2009.10.027. PMID 20079999.
  81. ↑ Chugh TD (2008). "Emerging and re-emerging bacterial diseases in India". Journal of Biosciences. 33 (4): 549&ndash, 555. doi:10.1007/s12038-008-0073-0. PMID 19208980.
  82. ↑ Antony B, Pinto H, Dias M, Shetty AK, Scaria B, Kuruvilla T, Boloor R (2010). "Spectrum of melioidosis in the suburbs of Mangalore, S West Coast of India". Southeast Asian J Trop Med Public Health. 41 (1): 169&ndash, 74.
  83. ↑ Vidyalakshmi K, Chakrapani M, Shrikala B, Damodar S, Lipika S, Vishal S (2008). "Tuberculosis mimicked by melioidosis". International Journal of Tuberculosis and Lung Disease. 12 (10): 1209&ndash, 1215.
  84. ↑ Prakash A, Thavaselvam D, Kumar A et al. (2014). "Isolation, identification and characterization of Burkholderia pseudomallei from soil of coastal region of India". Springerplus. 3: 438. doi:10.1186/2193-1801-3-438. PMC 4152474. PMID 25187882.
  85. ↑ Inglis TJ, Rolim DB, De Queroz Sousa A (2006). "Melioidosis in the Americas". American Journal of Tropical Medicine and Hygiene. 75 (5): 947&ndash, 954. PMID 17123994.
  86. 1 2 O'Sullivan BP, Torres B, Conidi G, et al. (2011). "Burkholderia pseudomallei infection in a child with cystic fibrosis: acquisition in the western hemisphere". Chest. 140 (1): 239&ndash, 242. doi:10.1378/chest.10-3336. PMID 21729895.
  87. ↑ Brilhante RS, Bandeira TJ, Cordeiro RA, et al. (2012). "Clinical-epidemiological features of 13 cases of melioidosis in Brazil". Journal of Clinical Microbiology. 50 (10): 3349–3352. doi:10.1128/JCM.01577-12. PMC 3457459. PMID 22814457.
  88. ↑ Katangwe T, Purcell J, Bar-Zeev N, Denis B, Montgomery J, Alaerts M, Heyderman RS, Dance DA, Kennedy N, Feasey N, Moxon CA (2013). "Human melioidosis, Malawi, 2011". Emerging Infectious Diseases. 19 (6): 981&ndash, 984. doi:10.3201/eid1906.120717. PMC 3713813. PMID 23735189.
  89. ↑ Morosini MI, Quereda C, Gil H, Anda P, Núñez-Murga M, Cantón R, López-Vélez R (2013). "Melioidosis in traveler from Africa to Spain". Emerging Infectious Diseases. 19 (10): 1656–1659. doi:10.3201/eid1910.121785. PMC 3810733. PMID 24047798.
  90. ↑ Struelens MJ, Mondol G, Bennish M, Dance DA (1998). "Melioidosis in Bangladesh: a case report". Transactions of the Royal Society of Tropical Medicine and Hygiene. 82 (5): 777&ndash, 778. doi:10.1016/0035-9203(88)90234-9.
  91. ↑ Hosen, Akram (30 Jul 2013). "Deadly bacteria in Gozipur soil". The Daily Star. Dhaka, Bangladesh. Archived from the original on 2013-07-21. Retrieved 30 Aug 2013.
  92. ↑ Dance DA, Smith MD, Aucken HM, Pitt TL (1999). "Imported melioidosis in England and Wales". Lancet. 353 (9148): 208. doi:10.1016/S0140-6736(05)77217-2. PMID 9923882.
  93. ↑ "Burkholderia pseudomallei" (PDF). Mahout Microbiology Review. 7: 4. 2013. Retrieved 24 April 2016.
  94. ↑ Limmathurotsakul, Direk; Golding, Nick; Dance, David A. B.; Messina, Jane P.; Pigott, David M.; Moyes, Catherine L.; Rolim, Dionne B.; Bertherat, Eric; Day, Nicholas P. J.; Peacock, Sharon J.; Hay, Simon I. (11 January 2016). "Predicted global distribution of Burkholderia pseudomallei and burden of melioidosis". Nature Microbiology. 1 (1): 15008. doi:10.1038/nmicrobiol.2015.8. PMC 4746747. PMID 26877885.
  95. ↑ Limmathurotsakul D, Wongratanacheewin S, Teerawattanasook N (2010). "Increasing Incidence of Human Melioidosis in Northeast Thailand". American Journal of Tropical Medicine and Hygiene. 82 (6): 1113–1117. doi:10.4269/ajtmh.2010.10-0038. PMC 2877420. PMID 20519609.
  96. ↑ Kanaphun P, Thirawattanasuk N, Suputtamongkol Y, et al. (1993). "Serology and carriage of Pseudomonas pseudomallei: a prospective study in 1000 hospitalized children in northeast Thailand". Journal of Infectious Diseases. 167 (1): 230&ndash, 233. doi:10.1093/infdis/167.1.230. PMID 7678106.
  97. ↑ Vuddhakul V, Tharavichitkul P, Na-Ngam N, et al. (March 1999). "Epidemiology of Burkholderia pseudomallei in Thailand". American Journal of Tropical Medicine and Hygiene. 60 (3): 4584–61. PMID 10466977.
  98. ↑ Kanai K, Dejsirilert S (August 1988). "Pseudomonas pseudomallei and melioidosis, with special reference to the status in Thailand". Japanese Journal of Medical Science and Biology. 41 (4): 123–157. doi:10.7883/yoken1952.41.123. PMID 3075004.
  99. ↑ Yang S, Tong S, Mo C, et al. (1998). "Prevalence of human melioidosis on Hainan Island in China". Microbiology and Immunology. 42 (9): 651–654. doi:10.1111/j.1348-0421.1998.tb02335.x. PMID 9802565.
  100. ↑ Chen YS, Chen SC, Wu TR, Kao CM, Chen YL (October 2004). "Seroprevalence of anti-flagellin antibody against Burkholderia pseudomallei in Taiwan". Japanese Journal of Infectious Diseases. 57 (5): 224–225. PMID 15507783. Archived from the original on 2008-06-19.
  101. ↑ Parkes, Helen M.; Shilton, Catherine M.; Jerrett, Ian V.; Benedict, Suresh; Spratt, Brian G.; Godoy, Daniel; O'Brien, Carolyn R.; Krockenberger, Mark B.; et al. (2009). "Primary ocular melioidosis due to a single genotype of Burkholderia pseudomallei in two cats from Arnhem Land in the Northern Territory of Australia". Journal of Feline Medicine and Surgery. 11 (10): 856–863. doi:10.1016/j.jfms.2009.02.009. PMID 19428280.
  102. ↑ Sprague LD, Neubauer H (2004). "Melioidosis in Animals: A review on epizootiology, diagnosis and clinical presentation". Journal of Veterinary Medicine. B, Infectious Diseases and Veterinary Public Health. 51 (7): 305&ndash, 320. doi:10.1111/j.1439-0450.2004.00797.x. PMID 15525357.
  103. ↑ Mollaret HH (1988). ""L'affaire du Jardin des plantes" ou comment le mélioïdose fit son apparition en France". Médecine et Maladies Infectieuses. 18 (Suppl 4): 643&ndash, 654. doi:10.1016/S0399-077X(88)80175-6.
  104. ↑ Corkeron ML, Norton R, Nelson PN (2010). "Spatial analysis of melioidosis distribution in a suburban area". Epidemiology and Infection. 138 (9): 1346&ndash, 1352. doi:10.1017/S0950268809991634. PMID 20092666.
  105. ↑ Chantratita N, Wuthiekanun V, Limmathurotsakul D, et al. (2008). Currie B, ed. "Genetic Diversity and Microevolution of Burkholderia pseudomallei in the Environment". PLoS Neglected Tropical Diseases. 2 (2): e182. doi:10.1371/journal.pntd.0000182. PMC 2254201. PMID 18299706.
  106. ↑ Lin HH; Chen YS; Li YC; e al. (2011). "Burkholderia multivorans acts as an antagonist against the growth of Burkholderia pseudomallei in soil". Microbiology and Immunology. 55 (9): 616–624. doi:10.1111/j.1348-0421.2011.00365.x. PMID 21752084.
  107. ↑ Inglis TJ, Garrow SC, Henderson M, Clair A, Sampson J, O'Reilly L, Cameron B (2000). "Burkholderia pseudomallei traced to water treatment plant in Australia". Emerging Infectious Diseases. 6 (1): 56&ndash, 559. doi:10.3201/eid0601.000110. PMC 2627980. PMID 10653571.
  108. ↑ Apisarnthanarak A, Khawcharoenporn T, Mundy LM (2012). "Flood-associated melioidosis in a non-endemic region of Thailand". International Journal of Infectious Diseases. 16 (5): e409–410. doi:10.1016/j.ijid.2012.01.013. PMID 22421023.
  109. ↑ Chierakul W, Winothai W, Wattanawaitunechai C, et al. (2005). "Melioidosis in 6 tsunami survivors in southern Thailand". Clinical Infectious Diseases. 41 (7): 982&ndash, 990. doi:10.1086/432942. PMID 16142663.
  110. ↑ Ko WC, Cheung BM, Tang HJ, Shih HI, Lau YJ, Wang LR, Chuang YC (2007). "Melioidosis outbreak after typhoon, southern Taiwan". Emerging Infectious Diseases. 13 (6): 896&ndash, 898. doi:10.3201/eid1306.060646. PMC 2792857. PMID 17553230.
  111. ↑ Inglis TJ, O'Reilly L, Merritt AJ, Levy A, Heath CH (2011). "The aftermath of the Western Australian melioidosis outbreak". American Journal of Tropical Medicine and Hygiene. 84 (6): 851&ndash, 857. doi:10.4269/ajtmh.2011.10-0480. PMC 3110376. PMID 21633018.
  112. ↑ Baker A, Pearson T, Price EP, et al. (2011). "Molecular Phylogeny of Burkholderia pseudomallei from a Remote Region of Papua New Guinea". PLoS ONE. 6 (3): e18343. doi:10.1371/journal.pone.0018343. PMC 3069084. PMID 21483841.
  113. ↑ Suputtamongkol Y, Chaowagul W, Chetchotisakd P, et al. (1999). "Risk factors for melioiosis and bacteremic melioidosis". Clinical Infectious Diseases. 29 (2): 408&ndash, 413. doi:10.1086/520223. PMID 10476750.
  114. ↑ Phe T, Vlieghe E, Reid T, et al. (2013). "Does HIV status affect the aetiology, bacterial resistance patterns and recommended empiric antibiotic treatment in adult patients with bloodstream infection in Cambodia?". Tropical Medicine and International Health. 18 (4): 485–494. doi:10.1111/tmi.12060. PMID 23294446.
  115. ↑ Kanai K, Kurata T, Akksilp S, et al. (1992). "A preliminary survey for human immunodeficient virus (HIV) infections in tuberculosis and melioidosis patients in Ubon Ratchathani, Thailand". Japanese Journal of Medical Science and Biology. 45 (5–6): 247&ndash, 253. doi:10.7883/yoken1952.45.247. PMID 1306871.
  116. ↑ Chierakul W, Wuthiekanun V, Chaowagul W, et al. (2005). "Short report: disease severity and outcome of melioidosis in HIV coinfected individuals". American Journal of Tropical Medicine and Hygiene. 73 (6): 1165&ndash, 1166. PMID 16354832.
  117. ↑ Suputtamongkol Y, Hall AJ, Dance DA, et al. (1994). "The epidemiology of melioidosis in Ubon Ratchatani, Northeast Thailand". International Journal of Epidemiology. 23 (5): 1082&ndash, 1089. doi:10.1093/ije/23.5.1082. PMID 7860160.
  118. ↑ Currie BJ, Jacups SP (December 2003). "Intensity of Rainfall and Severity of Melioidosis, Australia". Emerging Infectious Diseases. 9 (12): 1538–1542. doi:10.3201/eid0912.020750. PMC 3034332. PMID 14720392.
  119. ↑ Liu Y, Loh JP, Aw LT, Yap EP, Lee MA, Ooi EE (2006). "Rapid molecular typing of Burkholderia pseudomallei, isolated in an outbreak of melioidosis in Singapore in 2004, based on variable-number tandem repeats". Transactions of the Royal Society of Tropical Medicine and Hygiene. 100 (7): 687&ndash, 692. doi:10.1016/j.trstmh.2005.08.017. PMID 16343569.
  120. ↑ Sam IC, Puthucheary SD (2007). "Melioidosis and rainfall in Kuala Lumpur, Malaysia". Journal of Infection. 54 (5): 519&ndash, 520. doi:10.1016/j.jinf.2006.07.007. PMID 16965821.
  121. ↑ Baker, Anthony L.; Ezzahir, Jessica; Gardiner, Christopher; Shipton, Warren; Warner, Jeffrey M.; Wooten, R. Mark (23 September 2015). "Environmental Attributes Influencing the Distribution of Burkholderia pseudomallei in Northern Australia". PLOS ONE. 10 (9): e0138953. doi:10.1371/journal.pone.0138953. PMC 4580599. PMID 26398904.
  122. ↑ Whitmore, A; Krishnaswami, CS (1912). "An account of the discovery of a hitherto undescribed infectious disease among the population of Rangoon". Indian Medical Gazette. 47: 262–267.
  123. ↑ Strong, Richard P (1944). Stitt's Diagnosis, Prevention and Treatment of Tropical Diseases (7th ed.). Philadelphia: The Blakiston Company. p. 732.
  124. ↑ Vora SK (February 2002). "Sherlock Holmes and a biological weapon". Journal of the Royal Society of Medicine. 95 (2): 101–103. doi:10.1258/jrsm.95.2.101. PMC 1279324. PMID 11823558.
  125. ↑ Whitmore A, Krishnaswami CS (1912). "An account of the discovery of a hitherto undescribed infective disease occurring among the population of Rangoon". Indian Medical Gazette. 92: 262&ndash, 267.
  126. ↑ Barker A (19 June 2005). "Rise in melioidosis rates in NT". Australian Broadcasting Corporation. Retrieved 2007-06-24.
  127. ↑ Orellana C (November 2004). "Melioidosis strikes Singapore". Lancet Infect Dis. 4 (11): 655. doi:10.1016/S1473-3099(04)01190-9. PMID 15534940.
  128. ↑ C S Krishnaswami. "Morphia injectors' septicaemia". Indian Medical Gazette. 52 (1917): 296&ndash, 299.
Classification
External resources
  • Burkholderia pseudomallei genomes and related information at PATRIC, a Bioinformatics Resource Center funded by NIAID
  • Monograph on Melioidosis ( ISBN 978 0 444 53479-8); Elsevier Press, 2012, https://espaces.edu.au/melioidosis/melioidosis-a-century-of-observation-and-research
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.